



RNS Number : 1313B
EKF Diagnostics Holdings PLC
29 January 2024

EKF Diagnostics Holdings plc
("EKF" or the "Company")

Trading Update

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics business, provides an unaudited trading update for the year ended 31 December 2023 ("FY 2023").

The Company expects to report full-year revenues and adjusted EBITDA¹ in-line with management expectations, reflecting continued steady growth from the Point-of-Care division and ?-HB sales. Cash, net of bank borrowings, as at 31 December 2023, was £4.4m.

Good progress continues to be made in the Life Sciences division's fermentation capacity expansion. Purchase orders for precision fermentation services using the new facility have been received and the Company continues to onboard a number of customers. The Board anticipates that a steady build-up of revenues generated from the new fermentation capacity through 2024, alongside maintained growth across Point-of-Care and ?-HB sales.

EKF will announce its FY 2023 results in late March 2024 and provide further insight to expected performance for the current financial year at that time.

¹Earnings before interest, tax, depreciation and amortisation, excluding exceptional items and share based payments.

EKF Diagnostics Holdings plc www.ekfdiagnostics.com
Julian Baines, Executive Chair / Stephen Young, CFO **Tel: +44 (0)29 2071 0570**

Singer Capital Markets (Nominated Adviser & Broker) **Tel: +44 (0)20 7496 3000**
Aubrey Powell / Oliver Platts

Walbrook PR Limited **Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com**
Paul McManus / Alice Woodings **Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654**

About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)

EKF is an AIM-listed global diagnostics business focussed on:

- **Point-of-Care** analysers in the key areas of Hematology and Diabetes, as well as Central Laboratory products including clinical chemistry reagents, analysers and centrifuges
- **Life Sciences** services provide specialist manufacture of enzymes and custom products for use in diagnostic, food and industrial applications, as well as other higher value Contract Manufacturing services

EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

TSTFLFIDLLITFIS Anonymous (not verified) Trading Update 34052274 A Mon, 01/29/2024 - 07:00
LSE RNS Results and Trading Reports EKF